DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Chlorphen Mal Pseudoeph (Chlorpheniramine Maleate / Pseudoephedrine Hydrochloride) - Summary

 
 



SUMMARY

Chlorphen Mal/Pseudoeph HCl 0.8/9 mg Drops is an antihistaminic and decongestant drop for oral administration.

Chlorphen Mal/Pseudoeph HCl 0.8/9 mg Drops is indicated for symptomatic relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

See all Chlorphen Mal Pseudoeph indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Chlorphen Mal Pseudoeph (Chlorpheniramine / Pseudoephedrine)

Allergy (Allergies)
Source: MedicineNet Allergic Cascade Specialty [2017.01.13]
Title: Allergy (Allergies)
Category: Diseases and Conditions
Created: 7/23/1998 12:00:00 AM
Last Editorial Review: 1/13/2017 12:00:00 AM

Bee sting vaccine opens door to new allergy remedies
Source: Allergy News From Medical News Today [2017.01.09]
A bee vaccine developed in Australia is opening doors to new remedies for a range of other insect, plant and pollen allergies.

NIH-sponsored expert panel issues clinical guidelines to prevent peanut allergy
Source: Allergy News From Medical News Today [2017.01.06]
Recommendations focus on introducing peanut-containing foods to infants.An expert panel sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National...

Drug Allergy (Medication Allergy)
Source: MedicineNet Anal Itching Specialty [2016.11.21]
Title: Drug Allergy (Medication Allergy)
Category: Diseases and Conditions
Created: 4/14/2008 12:00:00 AM
Last Editorial Review: 11/21/2016 12:00:00 AM

Many doctors still don't know facts about penicillin allergy
Source: Allergy News From Medical News Today [2016.11.14]
If you think you're allergic to penicillin, but have never been tested, ask for a referral to an allergist to confirm the allergy.

more news >>

Clinical Trials Related to Chlorphen Mal Pseudoeph (Chlorpheniramine / Pseudoephedrine)

Study of AHIST in Seasonal Allergic Rhinitis Patients [Withdrawn]
Objectives: A) To gather pharmacodynamic measurements and assess blood levels of the active ingredients in AHIST over the dosage interval period of 12 hours. Hypothesis: Hysteresis curves plotting each active ingredient's blood levels over a 12-hour dosage interval will substantiate S5 Symptom Diary scores (IE: evidentiary therapeutic window data); B) To report subjective scores by subjects rating the efficacy of a single dose AHIST in relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over a 12-hour dosage interval. Hypothesis: Greater than 66% of subjects will document clinically significant relief over a 12-hour period from one dose of AHIST; C) Report any side effects or adverse drug reactions and rate the severity of any incidence. Hypothesis: Not more than one patient will have an adverse event significant enough to warrant withdrawal; side effects will be mild with the most frequently reported side effect occurring in less than 10% of patients—drowsiness.

Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt extended release test capsule formulation of chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a commercially available extended release oral suspension of chlorpheniramine polistirex/hydrocodone polistirex (Tussionex Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fed conditions.

Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents [Completed]

Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt extended release test capsule formulation of chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a commercially available extended release oral suspension of chlorpheniramine polistirex/hydrocodone polistirex (Tussionex® Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fasting conditions.

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study [Active, not recruiting]
This active vs active comparative trial will evaluate the safety and efficacy of incremental doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult patients with a history of seasonal allergic rhinitis. Hypotheses are defined by total nasal symptom scores (TNSS) recorded by subjects in diaries where efficacy will be established by statistical significance where p < 0. 05.

more trials >>


Page last updated: 2017-01-13

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015